Capricor Therapeutics (NASDAQ:CAPR) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $27.65 and traded as low as $18.98. Capricor Therapeutics shares last traded at $19.79, with a volume of 2,254,084 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CAPR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Roth Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a report on Friday, May 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Finally, LADENBURG THALM/SH SH raised shares of Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.67.

Capricor Therapeutics Stock Up 1.5%

The company has a market cap of $1.15 billion, a P/E ratio of -8.53 and a beta of 0.42. The stock has a 50 day moving average price of $25.90 and a two-hundred day moving average price of $27.65.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities analysts anticipate that Capricor Therapeutics, Inc. will post -0.49 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 50,000 shares of company stock worth $1,551,658. 9.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAPR. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics during the fourth quarter worth about $51,533,000. Tang Capital Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $43,516,000. Darwin Global Management Ltd. bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $23,168,000. Finally, SB Capital Management Inc acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $11,544,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.